1. Home
  2. ASMB vs ELUT Comparison

ASMB vs ELUT Comparison

Compare ASMB & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • ELUT
  • Stock Information
  • Founded
  • ASMB 2005
  • ELUT 2015
  • Country
  • ASMB United States
  • ELUT United States
  • Employees
  • ASMB N/A
  • ELUT N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • ELUT Medical Specialities
  • Sector
  • ASMB Health Care
  • ELUT Health Care
  • Exchange
  • ASMB Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • ASMB 100.5M
  • ELUT 111.2M
  • IPO Year
  • ASMB 2010
  • ELUT 2020
  • Fundamental
  • Price
  • ASMB $15.14
  • ELUT $4.12
  • Analyst Decision
  • ASMB Buy
  • ELUT Strong Buy
  • Analyst Count
  • ASMB 2
  • ELUT 2
  • Target Price
  • ASMB $35.00
  • ELUT $10.00
  • AVG Volume (30 Days)
  • ASMB 25.9K
  • ELUT 26.5K
  • Earning Date
  • ASMB 11-07-2024
  • ELUT 11-14-2024
  • Dividend Yield
  • ASMB N/A
  • ELUT N/A
  • EPS Growth
  • ASMB N/A
  • ELUT N/A
  • EPS
  • ASMB N/A
  • ELUT N/A
  • Revenue
  • ASMB $28,326,000.00
  • ELUT $24,782,000.00
  • Revenue This Year
  • ASMB $267.67
  • ELUT $9.65
  • Revenue Next Year
  • ASMB $46.15
  • ELUT $39.29
  • P/E Ratio
  • ASMB N/A
  • ELUT N/A
  • Revenue Growth
  • ASMB N/A
  • ELUT N/A
  • 52 Week Low
  • ASMB $8.16
  • ELUT $1.64
  • 52 Week High
  • ASMB $19.93
  • ELUT $5.24
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.09
  • ELUT 59.04
  • Support Level
  • ASMB $13.41
  • ELUT $3.57
  • Resistance Level
  • ASMB $15.36
  • ELUT $4.42
  • Average True Range (ATR)
  • ASMB 0.98
  • ELUT 0.32
  • MACD
  • ASMB -0.23
  • ELUT 0.08
  • Stochastic Oscillator
  • ASMB 41.07
  • ELUT 70.30

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: